Xilio Therapeutics Files 8-K
Ticker: XLO · Form: 8-K · Filed: Jun 2, 2025 · CIK: 1840233
Sentiment: neutral
Topics: financial-statements, exhibits, sec-filing
TL;DR
Xilio filed an 8-K, mostly financial statements and exhibits. No major news yet.
AI Summary
Xilio Therapeutics, Inc. filed an 8-K on June 2, 2025, reporting events as of May 31, 2025. The filing primarily concerns financial statements and exhibits, along with other events and a Regulation FD disclosure. No specific material events or financial figures were detailed in the provided excerpt.
Why It Matters
This filing indicates Xilio Therapeutics is providing updated information to the SEC, which could relate to ongoing business operations or regulatory compliance.
Risk Assessment
Risk Level: low — The filing is a routine disclosure of financial statements and exhibits, with no immediate indication of significant negative or positive events.
Key Players & Entities
- Xilio Therapeutics, Inc. (company) — Registrant
- 001-40925 (company) — Commission File Number
- 85-1623397 (company) — IRS Employer Identification No.
- 828 Winter Street, Suite 300 (company) — Principal Executive Offices Address
- Waltham, Massachusetts (company) — Principal Executive Offices Location
- 02451 (company) — Principal Executive Offices Zip Code
- (857) 524-2466 (company) — Registrant's telephone number
FAQ
What is the primary purpose of this 8-K filing by Xilio Therapeutics?
The primary purpose of this 8-K filing is to report financial statements and exhibits, along with other events and a Regulation FD disclosure, as of May 31, 2025.
When was this 8-K filing submitted to the SEC?
This 8-K filing was submitted to the SEC on June 2, 2025.
What is Xilio Therapeutics, Inc.'s principal executive office address?
Xilio Therapeutics, Inc.'s principal executive office is located at 828 Winter Street, Suite 300, Waltham, Massachusetts, 02451.
What is the Commission File Number for Xilio Therapeutics, Inc.?
The Commission File Number for Xilio Therapeutics, Inc. is 001-40925.
What is the earliest event date reported in this filing?
The earliest event date reported in this filing is May 31, 2025.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 2, 2025 regarding Xilio Therapeutics, Inc. (XLO).